Abstract: Background: Eurycoma longifolia is a well-documented herbal medicine that has gained widespread recognition due to its versatile pharmacological activities including anticancer, antimalarial, antimicrobial, antioxidant, aphrodisiac, anti-inflammatory, anxiolytic, anti-diabetic, antirheumatism and anti-ulcer. Plethora of in vitro and in vivo studies evidenced their excellent antiproliferative and anticancer efficacy against various types of human cancers.
INTRODUCTION
Cancer, also known as malignancy, is a group of diseases involving an abnormal growth of cells with the potential to invade other organs or parts of the body. The signs and symptoms of cancer depend on the type of cancer, where it is located, and/or where the cancer cells have spread. For example, breast cancer may present as a lump in the breast or as nipple discharge while metastatic breast cancer may present with symptoms of pain (if spread to bones), extreme fatigue (if spread to lungs), or seizures (if involve brain).
*Address correspondence to this author at the Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif 56000, Cheras, Malaysia; Tel: +6(0)391459567; Fax: +6(0)291459547; E-mail: anazrun@yahoo.com Most common signs and symptoms associated with cancer include unexplained severe pain or ache, unusual breast changes, extreme fatigue, blood in urine, blood in cough, abnormal bleeding, heavy night sweat, unexplained weight loss, unusual lump or swelling in any region of body, persistent ulcers/ulcerate that are not healing, prolonged cough, and a change in bowel movements. There are more than 100 types of cancer, including lung cancer, ovarian cancer, malignant melanoma, breast cancer, prostate cancer, colorectal cancer, cervical cancer, skin cancer, leukemia, and lymphoma.
American Cancer Society (ACS) recommended that there are seven warning signs or symptoms that need serious medical attention. These cautionary signs and symptoms include; 1) persistent chronic sore throat that is not healing, 2) change in bowel or bladder habits, 3) unusual heavy bleeding or fluid discharge (e.g., nipple discharge, chronic sore that is not healing and oozes transudate or exudates), 4) unusual lump in breast, testicles, or elsewhere in the body, 5) indigestion (usually chronic) or difficulty in swallowing, 6) apparent change in the color, size, shape, or thickness of a wart or mole, and 7) worse hoarseness or nagging cough. Though these conditions may arise from non-cancerous cause, anyone experiencing these signs or symptoms should consult to medical practitioners. Among various nonpharmacological and pharmacological interventions, the most common cancer therapeutic modalities include chemotherapy, radiation, and/or surgery.
Traditional herbal medicines have been well-documented as complementary and alternative medicines (CAMs) for the managment, prevention or cure of a wide range of human diseases including cancer [1, 2] , gastrointestinal diseases [3, 4] , hepatitis [5] , skin inflammatory disorders [6] [7] [8] , heart diseases [9] , blood disorders, joint problems, Parkinson's diseases [10] , respiratory issues, urinary tract infections, epilepsy [11] and muscle and bone disorders [12] . CAM has been growing throughout the healthcare industry, spurred by patient empowerment among the patient and doctor populations. Historically, allopathic medicines were considered as the alternative form of treatment because practitioners who dealt primarily with herbal interventions were providing healthcare to most of the patients. The switch from alternative herbal-based medicine to the present allopathic regimens has only occurred in the past century. Presently, according to the World Health Organization (WHO), only 10 to 30% of the healthcare is being delivered by allopathic practitioners; whereas, the remaining 70 to 90% of healthcare is still being provided by alternative healthcare providers. These alternative modalities range from self-care according to folk principles to care given in an organized health care system based on a traditional or common practice. Among the CAMs, Eurycoma longifolia Jack is well-documented herbal medicine in Southeast Asia. Different parts of this plant (roots, stem, leaves, bark etc.,) are currently being used for the treatment of various diseases in many countries in Asia. Besides this, recently Eurycoma longifolia has contributed a prominent role as CAM in herbal therapies, in the West.
Eurycoma longifolia, a potent medicinal herb in the family of Simaroubaceae, is known locally as Tongkat Ali in Malaysia, Tung saw in Thailand, Pasak bumi in Indonesia and cay ba bihn in Vietnam [13] . Eurycoma longifolia has gained remarkable recognition among various ethnic groups in Malaysia, China and South Africa due to its excellent pharmacological activities [14] [15] [16] . Eurycoma longifolia has also shown strong antiproliferative and anticancer activities against various types of human cancers including hepatocellular carcinoma, malignant melanoma, cervical cancer, ovarian carcinoma, breast cancer, colorectal cancer and lung cancer [17] [18] [19] [20] [21] . Besides its anticancer potential, Eurycoma longifolia has also been well-recognised due to its other pharmacological activities including aphrodisiac [22] [23] [24] [25] [26] , anti-malarial [27] [28] [29] , antibacterial [30, 31] , antiinflammatory [32, 33] , anxiolytic [34] , anti-diabetic [35, 36] , anti-ulcer [37] , anti-rheumatism [32, 38] antitumor [39, 40] and anti-osteoporotic activities [41, 42] .
Numerous in vitro and in vivo studies indicated promising potential of Eurycoma longifolia for the treatment of various types of human cancers. The current review was therefore aimed to summarize the convincing evidence for the pharmacological and therapeutic viability of Eurycoma longifolia in the treatment of human cancer. The potential molecular and translation mechanism for the anticancer ability of Eurycoma longifolia has also been critically discussed.
EURYCOMA LONGIFOLIA AND ITS BIOACTIVE COMPOUNDS

Bioactive Compounds Having Anti-proliferative and Anticancer Efficacy
Among various compounds isolated from Eurycoma longifolia, 16 compounds have shown strong antiproliferative and anti-cancer effects against various human cancer cell lines. These bioactive compounds include eurycomanone, eurycomanol, 13β, 21-dihydroxyeurycomanone, 14-hydroxyglaucarubol, eurycomalactone, eurycomadilactone, 5-iso-eurycomadilactone, 13-epi-eurycomadilactone, longilactone, 6-dehydroxylongilactone, canthin-6-one, 9-methoxycanthin-6-one, canthin-6-one 9-O-β-glucopyranoside, 14,15β-dihydroxyklaineanone, pasakbumin B, and pasakbumin C. The chemical structures of all these compounds having cytotoxic activities against various human cancers are presented in (Fig. 1) .
Their specificity against various human cancers is variable. Kuo et al. [20] demonstrated that eurycomalactone, longilactone, 14,15β-dihydroxyklaineanone, eurycomanone, and 13,21-dihydroeurycomanone showed strong antiproliferative and anticancer activities against lung cancer (A-549 cells). They have also tested the anti-proliferative activity and cytotoxicity of these compounds against MCF-7 cells and demonstrated that compounds such as eurycomalactone, 6-dehydroxylongilactone, 9-methoxycanthin-6-one, 14,15β-dihydroxyklaineanone, pasakbumin B and pasakbumin C have shown promising cytotoxicity against MCF-7 cells [1, 20] .
Cytotoxicity of eurycomanol, 13β,21-dihydroxyeurycomanone, 14-hydroxyglaucarubol, eurycomadilactone, 5-isoeurycomadilactone and 13-epi-eurycomadilactone has also been evaluated against many types of human cancers such as cervical carcinoma (HeLa cells), liver carcinoma (HepG2 cells), gastric carcinoma (MGC-803 and BGC-823 cells), intestinal cancers (HT-29 and LOVO cells), lung carcinoma (A-549 cells) and breast cancer (MCF-7 cells) using fluorouracil as a control [2] . The results demonstrated that the tested compounds exhibited a strong cytotoxicity against breast cancer (MCF-7 cells) and gastric carcinoma (MGC-803 cells); however, showed a moderate efficacy against other types of human cancers.
Analytical Tools
Generally, unknown compounds or chemical entities were verified by a collective approach using infrared spectroscopy, UV/visible spectroscopy, mass spectrometry, and X-ray analysis followed by 1 highly pure which make it difficult to use these techniques to generate highly confident data. Mass spectrometry is nowadays the most versatile analytic method for the detection of unknown chemical constituents from polyherbal formulations or plant extracts [43, 44] . For further identification and quantification, liquid chromatography furnished with mass spectrometry (LC-MS) is recognized as most reliable and powerful tool [45] [46] [47] .
14-hydroxyglaucarubol
Quassinoids are the most active and major constituents isolated/extracted from various species of Simaroubaceae family [48] . The analysis of chemical constituents of quassinoids is numerously performed using liquid chromatography, photodiode array or fluorescence and U.V/visible spectroscopic analysis. However, these methods were unable to detect and quantify non-chromophoric constituents of Eurycoma longifolia, such as eurycomanol [49, 50] . Hence, mass spectrometry can be the most reliable and sensitive approach to analyze most of the chemical constituents and secondary metabolites from Eurycoma longifolia [51, 52] . Recently, Han et al. [53] have analyzed the percentage purity of six major quassinoids including, 13(21)-epoxyeurycomanone, eurycomanone, 13,21-dihydroeurycomanone, longilactone, 14,15-dihydroxyklaineanone, and eurycomalactone of Eurycoma longifolia from dietary supplements tablets and capsules using LC-MS [53] . Near infrared (NIR) spectral database can be also be utilized for rapid screening of the test sample to verify their contents as labeled on the herbal products [54] .
EVIDENCE-BASED OVERVIEW OF ANTI-PROLIFERATIVE AND ANTICANCER ACTIVITIES OF EURYCOMA LONGIFOLIA AND ITS MEDICI-NALLY ACTIVE COMPOUNDS
Investigations on the cytotoxicity of a newly synthesized, isolated, purified drug entity or traditional herbal medicines are very crucial before further screening of their pharmacol-ogical activities. After establishing cytotoxicity, their antiproliferative and anticancer efficacies are screened using various in vitro cell culture and in vivo (murine and other animals) models. Numerous compounds/metabolites isolated from Eurycoma longifolia Jack have been investigated for anti-proliferative effects, cytotoxicity and anticancer efficacy. Some of these compounds have shown promising antiproliferative and anticancer efficacies against various types of murine or human cancers.
Cancer, also known as malignancy, is a group of diseases involving an abnormal growth of cells with the potential to invade other organs or parts of the body. Most common signs and symptoms associated with cancer include severe pain, abnormal bleeding, unexplained weight loss, a characteristic lump, ulceration, prolonged cough, and a change in bowel movements. The signs and symptoms can vary with the types of human cancer. There are more than 100 types of cancer, including lung cancer, ovarian cancer, malignant melanoma, breast cancer, prostate cancer, colorectal cancer, cervical cancer, skin cancer, leukemia, and lymphoma. The most common cancer therapeutic modalities include chemotherapy, radiation, and/or surgery.
Numerous studies evidenced that the water, methanolic, ethanolic or butanolic extract of Eurycoma longifolia Jack and various bioactive compounds isolated from this medicinal plant have shown promising anti-proliferative and cytotoxic effects against various human cancer cell lines including HepG2, HM3KO, Hela, CaOV-3, A-2780, MCF-7, HT-29, and A-549 cells.
Eurycomanone, one of the most bioactive medicinal compounds isolated from the extract of Eurycoma longifolia has shown strong anticancer efficacy against various types of human cancers including HepG2, HM3KO, Hela, CaOV-3, A2780, MCF-7, HT-29 and A549 cells. Wong et al. [39] evaluated the anti-proliferative and anticancer efficacy of the purified eurycomanone on the expression of selected genes of human lung adenocarcinoma (A549 cells) at a concentration range of 5 to 20 µg/mL. Eurycomanone significantly inhibited the proliferation of human A549 lung adenocarcinoma cells in a dose-dependent manner with lowest cell growth observed at 20 µg/mL ( Fig. 2A) . Further analysis showed that at 5.1 µg/mL concentration, eurycomanone inhibited 50% of the cell growth (GI 50 ). These results were in line with a previous study which was executed on cancerous liver cells [17] . The anti-proliferative potential of eurycomanone was also compared with cisplatin, a well-known chemotherapeutic agent for the treatment of lung cancer. Results showed that cisplatin also inhibited the proliferation of A549 cells in a dose-dependent manner at concentrations ranging from 0.2 to 15 µg/mL and the lowest cell growth was observed at 15 µg/mL [39] . Wong and co-workers explained that cisplatin (GI 50 = 0.58 µg/mL) was found to be ten-folds more potent than eurycomanone (GI 50 = 0.58 µg/mL) for the inhibition A-549 cells ( Fig. 2A) . Interestingly, results showed that even after the removal of the eurycomanone treatment (after 72 h), the normal cell growth efficacy was not restored (>30% cell growth was still inhibited) (Fig. 2B) . Eurycomanone had also reduced the colony formation effi- ciency (anchorage-independent growth) of A549 cells significantly compared to the DMSO (Fig. 2C ) [39] . They have also noticed a remarkable reduction in the mRNA expression of lung carcinoma-related biomarkers including hnRNP, p53 tumor suppressor protein, PHB, ANX1, and ERp28 within 72 h of treatment. These results indicated a promising antiproliferative and anti-clonogenic efficacy of eurycomanone against A-549 lung cancer cells [39] .
Mahfudh et al. [55] evaluated the cytotoxicity of eurycomanone against Hela cells using methylene blue staining assay, Hoechst 33258 nuclear staining, flow cytometry and TUNEL assay. They further investigated the mechanism of cytotoxicity of eurycomanone by examining the protein expression of p53, Bax and Bcl-2 using Western blotting and immunostaining assays. Eurycomanone showed selective cytotoxicity against various cancerous cell lines (MCF-7, HeLa, CaOv-3, HM3KO, and HepG2) but was least toxic against normal human cells (MDBK and Vero cells). The cytotoxicity of eurycomanone is mainly attributed to its ability to induce apoptosis in cancerous cells by inducing chromatin condensation, appearance of apoptotic bodies, and DNA fragmentation in cancerous cells treated with this potent medicinal compound [55] . These results were in line with a previous study in which authors demonstrated that eurycomanone was found very efficacious against various types of human cancer cell lines [56] .
Methanolic extract of Eurycoma longifolia has also been investigated against human leukemia cells (K-562) [57] . In this study, a wide range of in vitro experiments were performed including cell viability, clonogenic assay, annexin V-FITC/PI assay, Hoechst 33342 staining, cell cycle, and RT 2 profiler TM PCR array. The anticancer potential of Eurycoma longifolia was also evaluated by measuring the tumor volume, inhibition of tumor growth and histological examination using Balb/C nude mice. Their results showed a significant anti-proliferative and growth inhibition activity against K-562 cells treated with various fractions of Eurycoma longifolia. Potent cytotoxicity and anti-proliferative effects were observed after 48 h of treatment with IC 50 value of 1963 and 661 mg/mL, respectively [57] . In this study, authors have also observed a dose-and time-dependent cytotoxicity of K-562 cells at different concentrations of Eurycoma longifolia at various time points [57] . They further explored the anti-proliferative and cytotoxicity mechanisms of Eurycoma longifolia. By evaluating the biochemical parameters of early apoptosis (Annexin-V positive) and late apoptosis/necrosis (Annexin-V/PI positive), they suggested that treatment of K-562 cells with various fractions of Eurycoma longifolia caused induction of apoptosis in a dose-and time-dependent manner. Nuclear changes such as chromatin condensation and DNA fragmentation which are the hallmark features of apoptosis were also identified in K-562 cells treated with Eurycoma longifolia (Hoechst 33342 staining). A promising anti-leukemic potential of Eurycoma longifolia was also confirmed by an in vivo animal study that showed a remarkable decrease in the tumor volume, number of viable tumor cells (VC), increased numbers of apoptotic cells (AC) and the necrotic cells (NC) in the Eurycoma longifolia (TAF273)-treated mice compared to the control groups (Fig. 3) . Further analysis of histological micrographs using Image J software revealed a significantly higher percentage of necrosis in Eurycoma longifolia (TAF273)-treated group compared to the control group. The mean count of apoptotic cells were 2566 and 103611 in the control and TAF273 groups, respectively (Fig. 3) . These findings suggested that Eurycoma longifolia exhibits a strong antileukemic potential [57] . The anti-proliferative and anticancer efficacy of alcoholic and aqueous extracts of Eurycoma longifolia has also been investigated by other researchers [58] [59] [60] . Eurycoma longifolia has also been used in combination with Dipterocarpus obtusifolius and Tamilnadia uliginosa for the treatment of various types of human cancers [61] .
The standardized quassinoids extract of Eurycoma longifolia (SQ40) was also investigated for the treatment of human prostate cancer [62] . SQ40 is an extract that contains 40% (w/w) of quassinoids which was tested for antiproliferative and anticancer activities against the human prostate cancer using a series of in vitro and in vivo experiments. The cell viability analysis revealed that SQ40 showed a strong dose-dependent cytotoxicity against LNCaP cells (human prostate cancer cell line); however, showed no cytotoxicity against human normal prostate (RWPE-1) and liver (WRL-68) cells. The concentrations of SQ40 that cause maximal half inhibitory effects (IC 50 ) against RWPE-1, WRL-68 and LNCaP cell lines were 59.26 µg/mL, 27.69 µg/mL, and 5.97 µg/mL, which indicated that SQ40 exhibits potent cytotoxicity against human prostate cancer. The analysis of growth kinetics of LNCaP, RWPE-1 and WRL-68 cells using impedance-based cell sensing measurement system further validated that QS40 showed cytostatic effects at lower concentrations (2.5-10 µg/mL) and cytotoxic response at higher concentrations (20-80 µg/mL). A significant dose-dependent down-regulation of cell cycle regulatory proteins such as CDK4, CDK2, Cyclin D1 and Cyclin D3 and subsequent up-regulation of cell cycle inhibitory protein (p21 Waf1/Kip1 ) in SQ40-treated LNCaP cells further validated the anti-proliferative and cytotoxic mechanisms of this quassinoids extract against human prostate cancer [62] . The anticancer activity of SQ40 was also evidenced using the in vivo LNCaP tumor xenograft growth in nude mice. An intraperitoneal administration of SQ40 for a period of six weeks in prostate cancer induced nude mice showed a significant dose-dependent decrease in the tumor volume compared to the control groups (Fig. 4) . These findings evidenced that Eurycoma longifolia exhibit strong anticancer potential against human prostate cancer [62] . The potency of quassinoids extract of Eurycoma longifolia has also been demonstrated by other researchers [63, 64] . They suggested that the quassinoids from the leave extract of Eurycoma longifolia exhibits promising potential against A-549 (human lung cancer cells) and other human cancers.
Several other medicinal compounds of Eurycoma longifolia including eurycomanol, 13-β, 21-dihydroxyeurycomanone, 14-hydroxyglaucarubol, eurycomalactone, eurycomadilactone, 5-iso-eurycomadilactone, 13-epi-eurycomadilactone, longilactone, 6-dehyroxylongilactone, canthin-6-one, 9-methoxycanthin-6-one, canthin-6-one 9-O-betaglucopyranoside, 14,15 beta-dihydroxyklaineanone, pasakbumin B, and pasakbumin C have also shown strong antiproliferative and anticancer activities against a wide variety of human cancers in vitro and in vivo [1, 2, 20] . A summary of anti-proliferative and anticancer activities of Eurycoma longifolia and its medicinal compounds is presented in ( Table 1) .
The prime mode of cytotoxicity of Eurycoma longifolia and its medicinally active compounds in cancerous cells is the induction of apoptosis (programmed cell death) via the up-regulation of the expression of p53 (a tumor suppressor protein) and pro-apoptotic protein (Bax), and the downregulation of the expression of anti-apoptotic protein (Bcl-2) [17, 55] . However, other studies suggested that activation of Caspases (apoptotic signaling cascades) [65] and/or inhibition of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) have also been identified as the important molecular targets of Eurycoma longifolia and its medicinal compounds to provoke anti-proliferative and anticancer activities [32, 66] .
Apoptosis is a physiological cascade of programmed cell death to eradicate abnormal/cancerous cells while preserving the overall structure of surrounding tissue. It is a prime barricade to oncogenesis, hence, an important mechanism to maintain homeostasis within an organism. Among several regulators of apoptosis and suppressor of carcinogenesis, p53 play crucial role in regulating apoptosis of cancerous cells and maintaining internal environment constant [67, 68] . Generally, apoptosis is regulated by the two main pathways; an extrinsic "death receptor signaling" pathway and an intrinsic "mitochondria" pathway. Various regulatory proteins including Bcl-2, Bax and Caspases family members also impart prominent roles in the regulation of apoptosis. Because of its potent tumor suppressive effects, p53 is a fundamental molecular/pharmacological target for anticancer therapeutics [69] [70] [71] . It can be activated in response to 
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[ 58] oncogene activation, DNA damage, cellular abnormality or hypoxia, and trigger biological output such as programmed death of abnormal cells, cell-cycle arrest and modulation of autophagy [72] [73] [74] . p53 mainly functions as a transcriptional factor, and can trigger or stimulate variety of antiproliferative cascades by activating or suppressing key effectors genes [75, 76] .
Caspase family members have also been established as essential mediators of apoptosis [77] [78] [79] . These cell regulatory proteins are created within the cell as inactive zymogens that lack significant protease activity. They activate in response to molecular or chemical signals of cells death [80] . After receiving specific cell death signals, they started the cleavage and dismantling of cellular machinery (apoptosis) [81, 82] . Similarly, mitochondrial dysfunction, loss of survival signals, or DNA damage might cause activation of caspases may predispose to apoptosis. The inactivation or functional defect of caspases may lead to oncogenesis. On the other hand, over-expression of caspases may stimulate cellular suicide, and this may the basis for degenerative diseases such as Alzheimer's disease and Huntington's disease.
CONCLUSION
The critical analysis of the literature revealed that aqueous, methanolic, ethanolic, or butanolic extracts of various parts (roots, stem, bark, or leaves) of Eurycoma longifolia and its medicinally active compounds have shown potent antiproliferative and anticancer efficacy against various types of human cancers including hepatocellular carcinoma, malignant melanoma, cervical cancer, ovarian carcinoma, breast cancer, colorectal cancer and lung cancer. A plethora of in vitro and in vivo studies have demonstrated their safety, efficacy, tolerability, pharmacological efficacy and therapeutic feasibility against various types of human cancer cell lines. The antiproliferative and anticancer activity of Eurycoma longifolia is attributed to its ability to provoke induction of apoptosis (programmed cell death) via the up-regulation of the expression of p53 (tumor suppressor protein) and Bax (pro-apoptotic protein) and down-regulation of Bcl-2 (anti-apoptotic protein). Activation of caspases (apoptotic signaling cascades) and inhibition of NF-κB have also been recognized as the important molecular targets for Eurycoma longifolia and its medicinally active compounds. Eurycoma longifolia-mediated treatment of cancer cell lines have shown remarkable efficacy in downregulating the cell growth and causing nuclear condensation, DNA fragmentation, membrane blebbing and change in the cell morphology. Treatment of cancer induced animals with Eurycoma longifolia showed significant decrease in the cancerous lump size, tumor volume and cancer-related mediators locally and in the plasma. Fig. (4) . Anti-tumor activity of SQ40 against subcutaneous LNCaP cell tumors. LNCaP cells at 2 × 10 6 were injected subcutaneously into right flank of NC nude mice. SQ40 treatment was initiated when the tumor was palpable. Vehicle control (saline) and SQ40 were given intraperitoneally thrice a week for 6 weeks with a total of 18 doses. (A) Mean body weight and (B) tumor volume for each treatment versus the number of days after initial injection of LNCaP cells. (C) Representative images of tumors isolated from vehicle control, 5 mg/kg and 10 mg/kg of SQ40-treated animals. Each point represents the mean ± SEM of data (n = 6). ** indicates p<0.01 versus vehicle control [62] . Reprinted with permission from Tong et al. [62] (Copyright © 2015).
FUTURE PROSPECTS
Even though numerous studies have explored the pharmacological significance and therapeutic viability of Eurycoma longifolia and its bioactive compounds for the treatment of various types of human cancers, much has yet to be executed and learned. To gain further insight into the anticancer trends of Eurycoma longifolia, we have noticed substantial gaps in research which include but not limited to; 1) lack of integration of medicinal chemistry, biology, pharmacology and toxicology which could be a promising way to further explore the anticancer specificity of Eurycoma longifolia and its compounds against each specific type of human cancer, 2) lack of sufficient attention on pharmacologically active constituents and their determination, identification, standardization and structural manipulation for future developments of new structural and functional analogs, 3) lack of research on individual translational anticancer mechanism of most active medicinal compounds against various types of human cancers, 4) lack of comparative anticancer analysis of most active constituents of Eurycoma longifolia, 5) lack of sufficient in vivo and human clinical studies to further explore demographic specificity and variations, and 6) lack of sufficient safety profile and toxicity data to conduct human clinical trials. 
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